The global Bioprocess Technology Market is projected to reach USD 25.9 Billion in 2023 and is expected to register a CAGR of 15.1% during the forecast period. It is projected to generate a revenue of USD 106.1 Billion by the end of 2033.
With consumer awareness regarding bioprocess technology on the rise, companies are focusing on the launch of next-generation bioprocess products and engaging synergistic approaches for distribution and manufacturing through various market consolidation activities.
Research & Development Impetus Positively Impacts Market Outlook
Recent trends show an acceleration in the research and development activities on bioprocess technology. As new and innovative technology variants are produced, key players can hope to attract new end-user segments. This is also primarily due to vital support offered by governments across the globe to enhance bioprocess technologies. Hence, the forecast period could witness a slew of rapid, and advanced technological innovations to vastly alter the market landscape.
| Attribute | Details |
|---|---|
| Bioprocess technology Market Size 2023 | USD 25.9 Billion |
| Bioprocess Technology Market (2033) Market Size | USD 106.1 Billion |
| Value CAGR (2023 to 2033) | 15.1% |
| Contact Lenses Market Top Players Share in 2023 | 10% to 15% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As the global rate of chronic and infectious diseases skyrockets, the pharma industry is on the quest for innovative technologies. This is key to steadily bolstering the modern healthcare system that is heavily burdened. The research and developmental activities by key players could spill over into the pharmaceuticals sector, paving way for the utility of advanced bioprocess technologies. As we step into a brand new decade, enhancing preparedness for unforeseen medical crises, by developing vaccines has become critical.
Currently, the industry is fazed by an onslaught of strict regulatory policies by major governments. This could hamper the steadfast development and launch of these vital technologies into the market. Moreover, bioprocess technology adoption is impacted by high investment costs. As a result of high costs, technology penetration might be decelerated during the forecast period.
Principal Consultant
According to Future Market Insights (FMI), the global bioprocess technology market was valued at USD 22.5 Billion in 2022.
The growing focus on alternative medicines and preventive measures and ongoing advances in bioprocess technology is driving current sales figures. Expansion and product launches in emerging markets are key factors promoting market growth.
Short Term (2023 to 2026): The leading companies are focusing on the expansion of their manufacturing capabilities with high flexibility and rapid operations. They also are emphasizing the development and launch of next-generation bioprocess products. This is estimated to not only favor the sales of bioprocess technology but also augment the growth in the overall fermentation technology market.
Mid-term ( 2026 to 2029): The bioprocess product-development pipeline supports an outlook of continued healthy growth in the mid-term. Through sustained product innovations, the market holds the potential to garner an extensive consumer base. Furthermore, due to incumbent developments in technology new and diverse applications might be uncovered for the product during this phase.
Long-Term (2029 to 2033): In the long run, the pharma sector could emerge as one of the largest market stakeholders. This is primarily due to the application of the technology for manufacturing advanced vaccines and recombinant proteins. Towards the end of the forecast period, and beyond these technologies could emerge as an integral component of the modern healthcare and pharmaceutical industry.
The top bioprocess technology and bioprocess analyzer market players are Thermo Fisher Scientific Inc., Sartorius, Merck KGaA, Danaher Corporation, and Lonza Group AG among others. Future Market Insights expects the global bioprocess technology market to grow at a CAGR of 15.1% over the forecast period by 2033 end.
The primary factor for the preference of the single-use (disposable) bioreactor in the bioprocess industry is the production of different biopharmaceutical therapeutics, using the same facility, in minimum time and with minimum cost.
The rising demand for personalized treatment for diseases like cancer is expected to increase the demand for bioprocess therapies like cell therapy. The decreasing cost of genetic sequencing shortly has enabled the development of personalized treatment plans and targeted therapies, which are more effective than less-specific therapies because they focus on a patient’s genetic and molecular makeup.
Techniques for process intensification also are being applied to biosimilar manufacturing. The increasing use of biosimilars in developed countries of Europe and the United States will boost the speed of the bioprocess technology adoption for rapid production of biosimilars.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Favorable government policies for start-up companies, especially in developing countries are expected to create opportunities for the market players to invest in the bioprocess technology market.
Mergers, acquisitions & expansion of manufacturing facilities around the globe are expected to bose well for the market in the coming years. Introducing advanced bioprocess products to leverage untapped market opportunities will remain a key growth driver.
In 2023, the USA is estimated to account for over 89.6% value share in North America. The dominance is driven by increasing requirements of upstream equipment. Rising living standards, health consciousness, and increasing disposable incomes are boosting the demand for effective treatments with minimal side effects.
During the forecast period, the United States market is anticipated to grow at a CAGR of 15.1%, to attain a valuation of USD 106.1 billion by 2033.
The United Kingdom market will exhibit a 12.8% CAGR throughout the forecast period. The use of single-use technologies, personalized treatment of rare diseases, and increase use of biosimilars had led to a rise in the demand for bioprocess technology.
What will Support Bioprocess Technology Market Growth in India?
The India bioprocess technology market is likely to grow at a CAGR of 18.6% during the forecast period. It is expected to account for a market share of 52.4% in South Asia. Major factors that are supporting the growth of the Indian bioprocess technology market are the production of biopharmaceuticals like recombinant proteins and vaccines.
India also is known as a leading hub for vaccine manufacturing, which inevitably makes it a key market for bioprocess technology.
The German bioprocess technology market is likely to grow at a CAGR of 10.9% during the forecast period. It is expected to account for a share of 27.4% in the Europe market. The rise in the demand for biopharmaceuticals, and the need to reduce wastage, and prevent contamination are the major factors that will drive the demand for the bioprocess technology market in Germany.
The China bioprocess market technology is likely to grow at a CAGR of 10.3% during the forecast period. It is expected to hold a share of 45.9% in the East Asia bioprocess technology market.
With the advent of new technologies in recent years, the bioprocess technology market is growing and has become one of the most significant sectors in the healthcare industry. By product, upstream was the dominant segment in 2020, occupying a market share of 65.2% of revenue.
Based on end users, biotech/biopharmaceutical companies will continue dominating the global bioprocess technology market. The segment is expected to hold a market share of 44.0% in 2023. This is primarily fuelled by the technology application in the manufacture of antibodies, antibiotics as well as recombinant proteins.
| Start-up Company | Mission Barns |
|---|---|
| Country | United States |
| Description | Mission Barns utilized bioprocess technology for producing cultured meat. The technology is employed to isolate animal cells. It is then kept in a cultivator for further development. Essentially, the startup employs bioprocess technology to create meat alternatives |
| Start-up Company | SingCell |
|---|---|
| Country | Singapore |
| Description | SingCell is a Singapore-based startup focusing on stem cell therapy. The startup employs 3D microcarrier-based technology that can be used for allogeneic and induced pluripotent stem cells (iPSC). Through the use of bioprocess technology, the company creates affordable stem cell therapy solutions |
The bioprocess technology market players are primarily aiming at strategic expansions to consolidate growth in a competitive market. Key players are keen on harnessing the current public-private investment inflow for research and investment in the field. Through this, market players are striving to expand product utility for diverse sectors.
The greater the demand for bioprocesses products, the stronger the pipeline, which will lead to increased demand in the market. Leading industry players are focusing on the launch of next-generation biotherapeutics to treat serious life-threatening diseases.
Key Market Developments:
| Company | Thermo Fisher Inc. |
|---|---|
| Details | Thermo Fisher Scientific Inc. is one of the top dealers of scientific equipment. It is an American company that deals with instrumentation, consumables as well as software solutions |
| Recent Developments | In October 2018, Thermo Fisher Scientific announced a USD 50 million (€44 million) expansion at a CDMO plant in St Louis, Missouri, USA to add 16,000 L of single-use capacity due to extremely strong growth in demand for commercial biologics manufacturing. As per the company, the facility will be the largest outsourced single-use biologics site in North America. |
| Company | Lonza Group AG |
|---|---|
| Details | Lonza Group is a multinational manufacturing company. It is a Swiss company predominantly catering to manufacturing for pharmaceutical, and biotechnology as well as nutrition. |
| Recent Developments | In June 2020, Lonza developed a new innovative platform technology, New GSv9 TM media and feeds to maximize yield and batch-to-batch consistency to support recombinant protein production scale-up. This provides a robust culturing platform that can reproducibly generate high-quality, stable proteins. |
| Company | Danaher Corporation |
|---|---|
| Details | Danaher Corporation is a conglomerate, known for its company designs, and manufacturing of medical, industrial, as well as commercial products. It is an American company with headquarters in Washington D.C. |
| Recent Developments | In March 2020 Danaher acquired the Biopharma business of General Electric Life Sciences, which is a leading provider of instruments, consumables, and software. |
The bioprocess technology market is slated to attain USD 25.9 billion in 2023.
The growth rate of bioprocess technology market is 15.1%.
Surging demand for bioprocess technology from healthcare and pharmaceuticals.
Favorable government policies and expansion of manufacturing facilities.
Thermo Fisher Scientific Inc, Sartorius, and Merck Kga are crowding the marketplace.
1. Executive Summary | Bioprocess Technology Market
2. Market Overview
3. Market Background
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product
5.1. Up-Stream Equipment
5.1.1. Cell Culture Development Products
5.1.2. Lab-scale Bioreactors
5.1.3. Scale-up and Production Products
5.1.4. Testing Products
5.1.5. Probes and Accessories
5.2. Downstream Equipment
5.2.1. Downstream Purification
5.2.2. Buffer Preparation and Supply
5.2.3. Process Analytical Testing
5.2.4. Probes and Accessories
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End-User
6.1. Biopharmaceutical Companies
6.2. Contract Research Organization
6.3. Academic Institutes
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
7.1. Latin America
7.2. Europe
7.3. South Asia
7.4. Oceania
7.5. Middle East and Africa
8. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
9. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
10. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
12. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
13. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
14. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
15. Key Countries Market Analysis
16. Market Structure Analysis
17. Competition Analysis
17.1. Thermo Fisher Scientific Inc
17.2. Sartorius
17.3. Merck KGaA
17.4. Danaher Corporation
17.5. STADA Arzneimittel AG
17.6. Applikon Biotechnology B.V.
17.7. Lonza AG
17.8. Bio-Rad Laboratories
17.9. Agilent Technologies
17.10. Solida Biotech GmbH
17.11. Waters Corporation
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Technology Insights
View Reports
Bioprocess Technology Market
